Nimedine (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem/cilastatin, the active ingredient in Nimedine, is a carbapenem antibiotic presented as an intravenous formulation for parenteral use. It treats a range of serious bacterial infections in hospitalized adults. GNH USA supplies Nimedine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/cilastatin is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections.

- Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in mixed aerobic‑anaerobic infections. - Complicated urinary tract infections: eliminates resistant uropathogens to achieve resolution of infection. - Complicated skin and soft tissue infections: targets Gram‑negative and Gram‑positive organisms for effective healing. - Community‑acquired bacterial pneumonia: offers rapid bacterial clearance and symptom improvement. - Severe sepsis: delivers broad coverage to control systemic infection and organ dysfunction.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: localized skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases. - Injection site pain: discomfort at the infusion site. - Headache: mild, transient.

Serious or Rare Side Effects: - Seizures: especially in patients with CNS disorders or renal impairment. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Acute renal failure: due to nephrotoxic interactions. - Thrombocytopenia: low platelet count. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, assess patient-specific factors and monitor for adverse events.

- Renal function: adjust dosing in patients with impaired kidney function. - Allergy: avoid in individuals with known hypersensitivity to β‑lactam antibiotics. - Seizure risk: use cautiously in patients with a history of seizures or CNS disease. - Drug interactions: review concomitant medications that may affect renal clearance or increase neurotoxicity. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with several drugs; monitoring is essential.

Major Interactions (Avoid): - Valproic acid: increased serum levels may cause toxicity. - Cisplatin: additive nephrotoxicity risk. - Probenecid: reduces renal clearance, raising drug concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Loop diuretics: may increase risk of renal impairment. - Other β‑lactam antibiotics: potential additive toxicity, especially neurotoxicity.